Navigation Links
Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results
Date:11/15/2010

NEW YORK, Nov. 15, 2010, PRNewswire-Asia/ -- Tiens Biotech Group (USA), Inc. (the "Company" or "Tiens", NYSE AMEX: TBV), www.tiens-bio.com, today announced financial results for the third quarter and nine months ended September 30, 2010.

Revenue for the third quarter of 2010 was $10.4 million, compared to $9.4 million for the third quarter of 2009. Revenue for the nine months ended September 30, 2010 was $30.0 million, compared to $48.2 million for the first nine months of 2009.

Net income for the third quarter of 2010 was $1.9 million, or $0.02 per share, compared to net income of $2.9 million, or $0.03 per share, for the 2009 third quarter. For the nine months ended September 30, 2010, net income was $6.0 million, or $0.08 per share, compared to $22.2 million, or $0.29 per share for the first nine months of 2009.

The increase in revenue for the third quarter ended September 30, 2010 reflects an increase in domestic sales of 32%. The decrease in revenue for the nine months ended September 30, 2010 was mainly due to a decrease in international sales which reflects China's Administration of Quality Supervision, Inspection and Quarantine carrying out a national campaign against unsafe food and substandard products in 2008, which brought on a general slow-down and backlog of export clearances for Chinese food products. Upon the lifting of the regulations, overseas affiliated companies began to purchase more products, thereby increasing sales in the first three quarters of 2009. The decrease reflects no sales to Indonesian distributors during the first nine months of 2010 given they purchased more products in 2009 after the aforementioned 2008 product scarcity. The sales decline to Indonesia accounts for 57% of the total international revenue decrease for the nine months ended September 30, 2010.

In October, the Company relocated its corporate headquarters to its 250-acre Tiens International Health Industrial Park research and development, manufacturing and logistic facilities approximately four miles from its previous location. The Life Resources facility will incorporate manufacturing, warehouses, work plants, a power center and dormitories. The center positions the Company well to increase manufacturing capacity to meet future growth opportunities.

Other Highlights

Cost of sales for the third quarter of 2010 was $4.1 million compared to $3.1 million for the same period in 2009. For the nine months ended September 30, 2010, cost of sales was $10.6 million compared to $15.0 million for the same period in 2009. The increase in cost of sales for the third quarter of 2010, as compared to the like quarter of 2009, is due to the sale of products with higher costs.

Gross profit for the third quarter of 2010 was $6.2 million, a decrease of 0.9% compared to $6.3 million for the same period in 2009. The gross profit margin for the third quarter of 2010 was 60.1%, compared to 66.7% for the same period in 2009. For the nine months ended September 30, 2010, gross profit was $19.3 million, a decrease of 41.8% compared to $33.2 million for the same period in 2010, and the gross profit margin was 64.5% compared to 68.9% for the same period in 2009.

The decrease in profit margin for the third quarter of 2010 reflects Company products with more than 65% profit margins being 27.4% of revenues as compared to 31.1% in the third quarter of 2009 and  the U.S. dollar depreciating approximately 2% between September 30, 2009 and September 30, 2010. The Company's international sales are quoted in U.S. dollars and collected in RMB, therefore, gross profit margin decreased by the same percentage as the depreciation of the U.S. dollar.

Selling, general and administrative expenses were $4.1 million for the third quarter of 2010, an increase of 39.3% compared to $2.9 million for the same period in 2009. This increase was primarily due to a relative increase in bad debt expense. Selling, general and administrative expenses as a percentage of sales were 39.1% for the third quarter of 2010 compared to 30.9% for the same period in 2009. For the nine months ended September 30, 2010, selling, general and administrative expenses were $11.6 million, an increase of 15.6% compared to $10.1 million in the same period in 2009. This increase was mainly due to the aforementioned increase in bad debt expense. For the nine months ended September 30, 2010, selling, general and administrative expenses as a percentage of sales were 38.8%, compared to 20.9% for the same period in 2009.

As of September 30, 2010, Tiens had $128.5 million of retained earnings and total shareholders' equity of $195.3 million.

Jinyuan Li, Chairman, President and CEO of Tiens, said, "We are pleased to report an increase in domestic sales which we believe will continue in the future. Our total revenue decline should be temporary since both our domestic and global affiliated companies have not witnessed significant declines in their overall revenue. We are committed to expanding our international customer base and generating long-term domestic and international growth."

About Tiens Biotech Group (USA), Inc. www.tiens-bio.com

Tiens Biotech Group (USA), Inc. (NYSE AMEX: TBV) conducts its business operations from Tianjin, People's Republic of China. Tiens primarily engages in the research, development, manufacturing, and marketing of nutrition supplement products, including wellness products and dietary supplements.

Tiens derives its revenues principally from product sales to affiliated companies in China and internationally in 54 countries.  Since its establishment, Tiens has developed and produced 37 nutrition supplements, which include wellness products and dietary supplements. Tiens develops its products at its own product research and development center, which employs highly qualified professionals in the fields of pharmacology, biology, chemistry and fine chemistry. Tiens has obtained all required certificates and approvals from government regulatory agencies to manufacture and sell its products in China.

In China, Tiens conducts the marketing and sales of its products through its affiliated company, Tianshi Engineering. Tianshi Engineering markets and sells Tiens' products in China through chain stores, domestic affiliated companies, and its 92 branches. Outside of China, Tiens sells its products to affiliated companies in 54 countries who in turn sell through an extensive direct sales force, or multi-level marketing sales force. The Company's direct sales marketing program is subject to governmental regulation in each of these countries.

Certain statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934.  Such forward-looking statements are not necessarily indicative of future financial results, and may involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to: (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; whether Tianshi Engineering, the Company's affiliate which sells its products in China, obtains a direct selling license in China; and (v) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at http://www.sec.gov under "Search for Company Filings."CONTACT:Investor Relations

Debra BerlinerTiens Biotech Group (USA), Inc.

G. S. Schwartz & Co.Tel:   +86-22-8213-7594

Tel:  212-725-4500Fax:  +86-22-8213-7594

Fax: 212-725-9188Email: investor@tiens-bio.com

Email: dberliner@schwartz.comhttp://www.tiens-bio.com-Tables Follow-

TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2010 and 2009 (UNAUDITED)Three months ended September 30,

Nine months ended September 30,2010200920102009REVENUE - RELATED PARTIES

$

10,381,886

$

9,439,739

$

29,953,098

$

48,228,320COST OF SALES - RELATED PARTIES4,145,0143,144,65010,623,74214,997,118GROSS PROFIT6,236,8726,295,08919,329,35633,231,202SELLING, GENERAL AND  ADMINISTRATIVE EXPENSES4,060,8122,916,20211,627,45610,061,729INCOME FROM OPERATIONS2,176,0603,378,8877,701,90023,169,473Interest expense(117,165)(40,363)(117,165)(146,180)Interest income2,52376,1548,241262,701Other income (expense)120,665(16,122)(551,305)(89,554)OTHER (EXPENSE) INCOME, NET6,02319,669(660,229)26,967INCOME BEFORE INCOME TAXES 2,182,0833,398,5567,041,67123,196,440INCOME TAXES319,776544,6881,067,8991,027,404NET INCOME

$

1,862,307

$

2,853,868

$

5,973,772

$

22,169,036LESS: Net income attributable to the noncontrolling interest(141,849)(617,638)(605,989)(1,163,683)NET INCOME ATTRIBUTABLE TO THE SHAREHOLDERS OF THE COMPANY1,720,4582,236,2305,367,78321,005,353OTHER COMPREHENSIVE INCOME:Foreign currency translation adjustment2,826,688182,0283,951,957406,870COMPREHENSIVE INCOME4,547,1462,418,2589,319,74021,412,223COMPREHENSIVE INCOME ATTRIBUTABLETO THE NONCONTROLLING INTEREST312,35311,390819,21625,240COMPREHENSIVE INCOME ATTRIBUTABLE TO THE SHAREHOLDERS OF THE COMPANY

$

4,234,793

$

2,406,868

$

8,500,524

$

21,386,983EARNINGS PER SHARE, BASIC AND DILUTED

$

0.02

$

0.03

$

0.08

$

0.29WEIGHTED AVERAGE NUMBER OF SHARES, BASIC AND DILUTED71,333,58671,333,58671,333,58671,333,586TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETSAS OF SEPTEMBER 30, 2010 (UNAUDITED) AND DECEMBER 31, 2009September 30, December 31,20102009(Unaudited)A S S E T SCURRENT ASSETS:Cash$

7,632,304

$

1,848,328Accounts receivable, trade - related parties, net of allowance for doubtful accounts
of $1,538,200 and $1,419,178 as of September 30, 2010 and December 31, 2009, respectively10,795,74115,379,312Inventories5,287,6685,328,052Other receivables1,256,939995,657Other receivables - related parties45,040,77344,561,626Employee advances114,444115,673Prepaid expenses, net of allowance for doubtful accounts of $1,039,643 and $1,018,474
as of September 30, 2010 and December 31, 2009, respectively431,442658,193Prepaid taxes3,001,473407,534Total current assets73,560,78469,294,375PROPERTY, PLANT AND EQUIPMENT, net9,910,70410,124,483OTHER ASSETS:Construction in progress170,971,153125,572,621Construction deposits8,250,5201,405,997Intangible assets, net12,898,22912,864,295Other assets13,507,37011,847,937Total other assets205,627,272151,690,850Total assets

$

289,098,760

$

231,109,708L I A B I L I T I E S
A N D   S H A R E H O L D E R S'   E Q U I T YCURRENT LIABILITIES:Accounts payable

$

6,350,030

$

5,012,157Advances from customers - related parties13,045,7494,426,751Wages and benefits payable808,2281,484,852Short-term debt - related party8,958,000-Income taxes payable570,185-Contractor deposits204,451183,395Contractor payables35,554,58418,513,216Other payables 1,164,6771,151,551Other payables - related parties15,630,6253,326,110Total current liabilities82,286,52934,098,032NON-CURRENT LIABILITIESDeferred income11,470,05011,236,501Total non current liabilities11,470,05011,236,501Total liabilities93,756,57945,334,533EQUITY:Shareholders' equity of the Company:Common stock, $0.001 par value, 250,000,000 shares authorized,
71,333,586 issued and outstanding, respectively71,33471,334Paid-in-capital18,271,51818,042,189Statutory reserves16,465,14413,217,217Retained earnings128,490,119126,370,263Accumulated other comprehensive income 21,394,86418,262,123Total shareholders' equity of the Company184,692,979175,963,126Noncontrolling interest10,649,2029,812,049Total equity195,342,181185,775,175Total liabilities and equity

$

289,098,760

$

231,109,708TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE NINE MONTHS ENDED SEPTEMBER 30, 2010 AND 2009 (UNAUDITED)Nine months ended September 30,20102009CASH FLOWS FROM OPERATING ACTIVITIES:Net income

$

5,973,772

$

22,169,036Adjustments to reconcile net income to cash provided by (used in) operating activities:Bad debt expense88,205(902,297)Depreciation1,172,5971,662,206Amortization252,075291,418Interest expense117,165(9,357)Gain on sale of assets(43,377)(14,846)Rental expense borne by a related party246,623-(Increase) decrease in assets:Accounts receivable, trade - related parties4,742,77210,678,476Other receivables(237,041)(121,058)Other receivables - related parties (92,265)(1,306,527)Inventories166,3372,801,809Employee advances3,579(80,873)Prepaid expense 236,536(336,620)Increase (decrease) in liabilities:Accounts payable1,195,483(1,687,613)Advances from customers - related parties8,401,340808,830Wages and benefits payable(697,018)(768,334)Deferred income taxes217,131-Other taxes payable(2,202,718)(31,337)Other payables(8,613)(176,274)Other payables - related parties 13,972,418(76,484)Net cash provided by operating activities33,505,00132,900,155CASH FLOWS FROM INVESTING ACTIVITIES:Proceeds from disposal of a subsidiary700,000-Collections from loans to local government -105,208Construction deposits(6,381,248)(3,465,755)Contractor deposits16,99085,498Addition to construction in progress(37,556,932)(26,936,754)Equipment deposits(1,414,417)(8,700,872)Proceeds from sales of properties2,668,07517,041Purchase of equipment and automobiles(742,954)(1,755,815)Net cash used in investing activities(42,710,486)(40,651,449)CASH FLOWS FROM FINANCING ACTIVITIES:Loan from (repayment to) related parties14,826,000(3,946,050)Increase in paid in capital-245,030Net cash provided by (used in) financing activities14,826,000(3,701,020)EFFECT OF EXCHANGE RATE CHANGES ON CASH163,461100,433NET INCREASE (DECREASE) IN CASH5,783,976(11,351,881)CASH, beginning of period1,848,32844,854,511CASH, end of period

$

7,632,304

$

33,502,630Supplemental disclosures of cash flow informationCash paid during the period for:Interest

$

-

$

105,817Income taxes

$

993,857

$

871,764TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES REVENUE BY REGIONThree months endedSeptember 30,20102009

ChangeChina  

$  6,152,896

$ 4,663,939

31.9%International

$  4,228,990

$ 4,775,800

-11.4%Total

$10,381,886

$ 9,439,739

10.0%Nine months endedSeptember 30,20102009

ChangeChina  

$17,351,251

$17,076,163

1.6%International

$12,601,847

$31,152,158

-59.5%Total

$29,953,098

$48,228,320

-37.9%
'/>"/>

SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
2. Tiens Biotech Group (USA) Reports First Quarter Results
3. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
4. Tiens Biotech Group (USA) Reports First Quarter Results
5. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
6. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
7. Yongye Biotechnology International Retains CCG Investor Relations
8. ThirdBiotech Announces Kemeta as Newest Sponsor
9. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
10. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
11. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016  Allergan plc (NYSE: AGN ) a ... Saunders , Allergan,s CEO and President, will be featured ... at the RBC Capital Markets Healthcare Conference on Tuesday, ... New York Palace Hotel in New York, ... and can be accessed on Allergan,s Investor Relations web ...
(Date:2/10/2016)... ... February 10, 2016 , ... LATHAM, NEW YORK... ... SPIE Photonics West conference in San Francisco’s Moscone Center from February 16-18, ... same venue. , These latest InGaAs PIN diode standard packages feature a TO-46 ...
(Date:2/10/2016)... ... 10, 2016 , ... Global Stem Cells Group, ... Global Stem Cells Network (GSCN) and its affiliate Global Medical Training Network ... adipose and bone marrow therapies. , Through the new collaboration, Global Stem ...
(Date:2/9/2016)... N.J. , Feb. 9, 2016  Regenicin, ... biotechnology company specializing in the development and commercialization ... of damaged tissues and organs, recently reported the ... the first quarter of 2016. Lonza ... the new 2015 fiscal year in the process ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/2/2016)... 2, 2016   Parabon NanoLabs (Parabon) ... Army Research Office and the Defense Forensics and ... of the company,s Snapshot Kinship Inference ... more generally, defense-related DNA forensics.  Although Snapshot is ... appearance and ancestry from DNA evidence), it also ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):